Genetic Cell Therapy in Anti-Aging Regenerative Cosmetology

As post-WWII baby boomer approaching age 80, Anti-Aging Regenerative Cosmetology (AARC) has been developed and patented for beautifying and strengthening the human body using live cells;to enhance the appearance and function of various bodily parts to provide health and aestheticism of human being throughout life. It is a combined cosmetic and preventive medicine to intervene with and to correct the undesirable phenotypic expression of aging. The intrinsic properties of myoblasts and foreskin fibroblasts in development and regeneration are harnessed to formulate a genetic cell therapy program which is safe and efficacious as previously been tested in FDA Phase III clinical trials. Myoblasts are selected for strength development and foreskin fibroblasts for tenacity and smooth-to-the-touch. Both cell types are highly mitotic and non-carcinogenic. In additional to providing large quantities of nuclei as regenerative gene medicine, and of mitochondria as energy generators, myoblasts secret tumor necrosis factor alpha (TNF-α) for skin whitening and melanoma prevention. Myoblasts, because of their small size, spindle shape, and resilience, grow readily on collagen and laminin within wrinkles of skin surfaces, thus enhancing the color, luster, and texture of the skin “plated” with them. Alternatively, they can be injected subcutaneously as cell filler to reduce wrinkles. Intramuscular injection of myoblasts can augment the size, shape, consistency, tone, and strength of muscle groups, improving the lines, contours, and vitality to sculpt a youthful appearance. By improving cell genetics and organ functions, the program holds promise to sustain the human subject in good health and appearance, with a good quality of life and life prolongation.

Changing the paradigm：the potential for targeted therapy in laryngeal squamous cell carcinoma

Laryngeal squamous cell carcinoma(LSCC) remains a highly morbid and fatal disease. Historically, it has been a model example for organ preservation and treatment stratification paradigms. Unfortunately, survival for LSCC has stagnated over the past few decades. As the era of next-generation sequencing and personalized treatment for cancer approaches, LSCC may be an ideal disease for consideration of further treatment stratification and personalization. Here, we will discuss the important history of LSCC as a model system for organ preservation, unique and potentially targetable genetic signatures of LSCC, and methods for bringing stratified, personalized treatment strategies to the 21^(st) century.

Multi-objective steady-state optimization of two-chamber microbial fuel cells

A microbial fuel cell(MFC)is a novel promising technology for simultaneous renewable electricity generation and wastewater treatment.Three non-comparable objectives,i.e.power density,attainable current density and waste removal ratio,are often conflicting.A thorough understanding of the relationship among these three conflicting objectives can be greatly helpful to assist in optimal operation of MFC system.In this study,a multiobjective genetic algorithm is used to simultaneously maximizing power density,attainable current density and waste removal ratio based on a mathematical model for an acetate two-chamber MFC.Moreover,the level diagrams method is utilized to aid in graphical visualization of Pareto front and decision making.Three biobjective optimization problems and one three-objective optimization problem are thoroughly investigated.The obtained Pareto fronts illustrate the complex relationships among these three objectives,which is helpful for final decision support.Therefore,the integrated methodology of a multi-objective genetic algorithm and a graphical visualization technique provides a promising tool for the optimal operation of MFCs by simultaneously considering multiple conflicting objectives.

Genetically modified human umbilical cord blood cells as a promising strategy for treatment of spinal cord injury

Spinal cord injury （SCI） continues to be a pressing health and social problem. The injury leads to neuronal and glial cell death accompanied by degeneration of nerve fibers. There are currently no particularly effective treatments. SCI causes profound disabil- ity of people affected and has attracted increased attention in the international field of neuroregeneration. For the past two decades, much hope has been placed in cell therapies for the restoration of both structure and function of the injured spinal cord. Embryonic and neural stem cells, olfactory ensheathing cells, microglia-like cells, Schwann cells, mesenchymal stem cells.

Extensive supporting cell proliferation and mitotic hair cell generation by in vivo genetic reprogramming in the neonatal mouse cochlea

Subject Code:H13With the support by the National Natural Science Foundation of China,the research team led by Prof.Li Huawei(李华伟)at the Otorhinolaryngology Department,Affiliated Eye and ENT hospital,State Key Laboratory of Medical Neurobiology of Fudan University,achieved the mitotic hair cell generation through agenetic reprogramming procedure,which was published in the Journal of Neuroscience(2016,36(33):8734—8745).

Generation of genetically modified olfactory ensheathing cells that secrete VEGF: Potential application in cell-based treatment of leukoaraiosis

Objective: We aimed to provide an alternative cell source for cell therapy in leukoaraiosis(LA). Methods: Olfactory ensheathing cells(OECs) from the olfactory bulb were isolated,cultured, and purified. Next, the lentivirus carrying human VEGF165 gene was constructed and transfected into OECs. Results: The proliferative capacity of primary OECs was strong. OECs were infected with different multiplicity of infection. The expression level of VEGF was confirmed by real-time PCR with specific primers for GAPDH and VEGF, indicating that the genetically engineered OECs-VEGF produced VEGF with functional activity. Conclusions: Our data showed that these engineered OECs-VEGF highly express functional VEGF and retain the characteristics of astrocytes and Schwann cells,providing an alternative cell source for cell therapy in LA.